Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females\* aging 18-45 years.~2. Body weight ranging between 50 and 100 Kg.~3. Previous experience with the consumption of sedatives (alcohol, cannabis, benzodiazepines, GHB or other hypnotics).~4. Absence of abnormalities in the screening ECG and blood/urine tests.~5. Agree with the study procedures and signature of the informed consent.~   * Women of childbearing potential must have a negative pregnancy test prior to randomization into the study and commitment to use at least one of these birth control methods: male or female condom with or without spermicide, cap, diaphragm or sponge with or without spermicide, intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence during the study. Condom use is considered as an additional method of contraception only and cannot be the only method of contraception used as not been considered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines.~Based on ICH, M3 (R2) 2009 a woman is considered of childbearing potential: fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include tubal ligation, hysterectomy, bilateral oophorectomy.~Exclusion Criteria:~1. Prior history of medical or psychiatric adverse reaction following GHB consumption.~2. Current substance use disorder (DSM-V, dependence, addiction) of any drug or substance of abuse.~3. Prior history of substance use disorder (DSM-V, drug use disorder or addiction) of any drug or substance of abuse (except nicotine).~4. Smokers\>10 cigarettes/day.~5. History of any physical condition or major surgery within the previous three months.~6. History of individual psychiatric conditions or schizophrenia in first-degree relatives.~7. History of gastrointestinal, hepatic, renal diseases or other conditions which, in opinion of the investigator, may affect drug absorption, distribution, metabolism or elimination.~8. Alcohol intake higher than 4 units/day (40 g) in men or 2 units/day (20 g) in women.~9. Positive urine drug test (Amphetamines, Barbiturates, Benzodiazepines, Cocaine, MDMA, Methamphetamine, Morphine/Opioids, Methadone, tricyclic antidepressants, THC)~10. HIV infection, chronic hepatitis C (IgG VHC) or B (HBsAg).~11. Lactose intolerance~12. Pregnancy, lactation, or planned pregnancy during the study period.~13. Current or recent pharmacological treatment (≥3 doses per week) in the last 2 weeks~14. Blood donation in the 3 previous months~15. Participation in another clinical trial in the previous 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- COBI period (5 days) + Placebo period (5 days) (Type: EXPERIMENTAL): volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB
- Placebo period (5 days) + COBI period (5 days) (Type: EXPERIMENTAL): volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB.

Based on this trial design, predict the completion outcome and termination type (if applicable).